Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes
US9301983B2 · kind B2 · utility
12Cited by
2References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2014 |
| Grant date | Apr 5, 2016 |
| Priority date | — |
| Expiry date | Mar 7, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2400/173
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.